Resiquimod Sulfate

3 trials 2 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

0 Completed trials

2 Sponsors

18 Countries

Phase II/III

Phase II

Phase II/III: 1 Phase II: 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Sponsors using this IMP

Eikon Therapeutics Inc. 2 Institut Bergonie 1

All trials

3 total

A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer. Pending

2025-525013-23-00 Phase II 6 countries Eikon Therapeutics Inc.
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Phase II/III 15 countries Eikon Therapeutics Inc.
AGADIR : Atezolizumab combined with EIK10001 (BDB001) and Immunogenic Radiotherapy in Patients with Advanced Solid Tumors Recruiting

2023-509492-16-00 Phase II 1 country Institut Bergonie

Showing 1–3 of 3 trials

← All drugs A–Z